Impact of facility type on survival after pancreatoduodenectomy for small pancreatic adenocarcinoma (≤ 2 cm)

Background: Previous studies have demonstrated that even small pancreatic cancers are associated with poor survival. The role of facility type on survival in this setting is unknown. Study design: The National Cancer Database (NCDB) was utilized. Patients who underwent pancreatoduodenectomy for adenocarcinoma <= 2 cm in Academic/Research Cancer Programs (ACPs) were compared to Non-Academic Cancer Programs (NACPs). Results: A total of 4672 patients were identified. Surgery at ACPs was associated with a lower rate of positive margins (14% vs 17%,P < .0001) and a higher rate of lymphadenectomy >= 15 nodes (49.6% vs 36.3%,P < .0001). Over 75% of the ACPs facilities were high volume vs 25.5% among NACPs. There was no difference in the odds of delivering chemotherapy in the neoadjuvant or adjuvant setting between ACPs and NACPs. The median survival at ACPs was 29.4 months vs 25.7 months at NACPs (Log-rank test:P < .0001). ACPs were associated with improved survival, adjusted Hazard Ratio: 0.88, 95%Cl:0.81 -0.96. Conclusion: Pancreatoduodenectomy for small pancreatic cancers at ACPs is associated with improved survival compared to NACPs. Published by Elsevier Inc.

Automated summary

The study found that patients who underwent pancreatoduodenectomy for small pancreatic cancers in Academic/Research Cancer Programs (ACPs) had lower rates of positive margins and higher rates of lymphadenectomy compared to patients in Non-Academic Cancer Programs (NACPs). ACPs were associated with improved survival compared to NACPs, with a median survival of 29.4 months at ACPs versus 25.7 months at NACPs.